Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Limosilactobacillus reuteri & Metabolic syndrome (MetS)

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

NCT02972567 - PROSIR - Limosilactobacillus reuteri V3401 & Metabolic syndrome (MetS)

This randomized, double-blind, crossover, placebo-controlled, and single-centre treatment trial revealed that no differences were observed between the groups (1).

References

(1) Tenorio-Jiménez et al. 2019 Nutrients 11: 1761

see also:
[Metabolic Syndrome (MetS) & Drugs/Treatments](brain://qa7kZCE8GEiP_o26iSCYew/MetabolicSyndromeMetS…

References (Sources)

Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR)
Tenorio-Jiménez et al. 2018
Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study
Tenorio-Jiménez et al. 2019 Nutrients 11: 1761
Therapeutic advances in non-alcoholic fatty liver disease (NAFLD): A microbiota-centered view
Chen et al. 2020l

AI Chat

5/29/2026

Chat with our artificial intelligence:

Start chat!